

A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata (Rezolve AA)

P724

David Rosmarin¹, Neil Sadick^{2,3}, Timothy G. Rodgers⁴, Edward Lain⁵, Lawrence Osman⁶, Stephen Schleicher⁷, Adam Reich⁸, Jacek C Szepietowski⁹, Agnieszka Owczarczyk-Saczonek¹⁰, Wojciech Baran⁹, Bartłomiej Kwiek¹¹, Michal Torz¹², Jacek Zdybski¹³, Sohail Chaudhry¹⁴, Zachary Lee¹⁴, Heng Xu¹⁴, Yi Liu¹⁴, Brian Lewis¹⁴, Katie Mellskog¹⁴, Lucinda M. Elko-Simms¹⁴, Christie Fanton¹⁴, Mary Tagliaferri¹⁴, Jonathan Zalevsky¹⁴, Charles W. Lynde^{15,16}

¹Indiana University School of Medicine, Indianapolis, IN, United States; ²Department Of Dermatology, Weill Cornell Medicine, New York, NY, United States; ³Sadick Research Group, New York, NY, United States; ⁴North Texas Center for Clinical Research, Frisco, TX, United States; ⁵Austin Institute for Clinical Reserach, Austin, TX, United States; ⁶Osman Dermatology, Northridge, CA, United States; ⁷DermDox Centers for Dermatology, Sugarloaf, PA, United States; ⁸Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland; ⁹Department of Dermatology, Venereology, and Allergology, Wroclaw Medical University, Wroclaw, Poland; ¹⁰Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Olsztyn, Poland; ¹¹Klinika Ambroziak Dermatologia, Lazarski University, Warsaw, Poland; ¹²Dermaceum Centrum Badań Klinicznych, Wroclaw, Poland; ¹³Dermedic Jacek Zdybski, Ostrowiec Świętokrzyski, Poland; ¹⁴Nektar Therapeutics, San Francisco, CA, United States; ¹⁵Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada; ¹⁶Lynde Institute for Dermatology, Markham, ON, Canada

BACKGROUND

- Prevalence of alopecia areata (AA) is 0.1-0.2% with calculated lifetime risk of 2%¹
- 6.7 million people in the US and 160 million worldwide have AA¹
- AA can start at any age and 80% of patients are younger than age 40²
- Patchy alopecia areata, alopecia totalis, and alopecia universalis are the predominant types of alopecia areata³
- 10–20% of the patients will develop alopecia totalis²
- AA causes substantial emotional and psychosocial distress¹
- Alopecia areata often occurs with other autoimmune conditions such as thyroid disease, atopic dermatitis, inflammatory bowel disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus and vitiligo¹
- Biopsies from patients with AA show perifollicular lymphocytic infiltrate (CD4+ and CD8+ T cells) around the anagen phase hair follicle⁴ and a significant reduction in regulatory T-cells (Treg)⁵

Why We Need Additional Therapies for Severe Alopecia Areata

- Majority of patients do not achieve adequate disease control with the standard of care therapies (baricitinib and ritlecitinib)⁶
- Currently available systemic therapies may be limited by their safety profile
 - JAK inhibitors (like baricitinib, ritlecitinib) carry multiple black boxed warnings⁷
- AA frequently recurs after a patient stops taking oral JAK inhibitors⁸
- The limited armamentarium of approved drugs with an adequate benefit-risk ratio represent major challenges in the field⁹
- New strategies aimed at inducing deep and potentially therapy-free remission are needed⁹

Figure 1: Rezpegaldesleukin (REZPEG): Novel Treatment Approach for Auto-immune Disorders






Figure 2: Phase 1b Study of REZPEG in Atopic Dermatitis (AD) Sustained Benefit Observed After 12-Weeks of Therapy¹¹



Phase 2b Study Evaluating REZPEG Potential in Patients with Moderate-to-Severe AD is Ongoing (NCT06136741)


Figure 3. Central Role of T Regulatory Cells in Immune Homeostasis



Tregs are crucial for immune homeostasis and the prevention of autoimmune conditions.¹²

STUDY DESIGN

Figure 4: Phase 2b Study for Patients with Severe Alopecia Areata



Phase 2b Study for Patients with Alopecia Areata

- This trial is a Phase 2b, randomized, double-blinded, placebo-controlled, international, multicenter study of REZPEG vs placebo for JAK-inhibitor and biologic-naïve patients with severe to very-severe AA.
- Patients will be randomly assigned in a 3:3:2 ratio to 2 different REZPEG dosing regimens vs. placebo, administered subcutaneously, during the 36-week treatment period.
- All patients will be followed for 24-weeks, following the treatment period.

ACKNOWLEDGMENTS

This study is funded by Nektar Therapeutics, San Francisco, CA. The study was or will be approved by the institutional review board of each participating site, and informed consent from all patients is required for study participation.

ABBREVIATIONS

Treg, T-regulatory; SEM, Standard error of the mean (continuous endpoint using observed data); LS Mean, least square mean; MMRM, Mixed Model for Repeated Measures; SAP, statistical analysis plan *EASI Improvement results are LS mean percent change from baseline obtained from MMRM as specified in the SAP defined in the protocol (generated by independent statistical audit firm)

REFERENCES

- National Alopecia Areata Foundation. <https://www.naaf.org/alopecia-areata>. Accessed April 2, 2024;
- Villasante Fricke AC, Miteva M. *Clin Cosmet Investig Dermatol*. (2015) 8: 397-403;
- Alopecia areata: Overview, symptoms, & causes. National Institute of Arthritis and Musculoskeletal and Skin Diseases. <https://www.niams.nih.gov/health-topics/alopecia-areata>. Updated April 2021. Accessed April 2, 2024;
- Gregoriou, S, et al. *Expert Review of Dermatology* (2011) 6(5): 537-548;
- Speiser JJ, et al. *J Cutan Pathol*. (2019) Sep;46(9):653-658.
- Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. *Clin Rev Allergy Immunol*. (2021) 61(3): 403-423;
- Mikhaylov D, et al. *Ann Allergy, Asthma, Immuno* (2023) 130(5) 577-592;
- Wang, Eddy H.C., et al. *Journal of Investigative Dermatology* (2018).138(9): 1911-1916;
- Malhotra K, Madke B. *Int J Trichology*. (2023) 15(1): 3-12.
- Fanton C, et al. *J Transl Autoimmun*. (2022) 5: 100152.
- Silverberg, J. et al. "LBA 6685: Efficacy and Safety of Single Agent Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study." European Academy for Dermatology and Venereology Annual Meeting, Berlin, Germany, October 11-14, 2023.
- Lykhophy V, et al. *Genes Immun*. (2023) Epub ahead of print

Key eligibility criteria

- Adult patients (males aged 18-60 years; females aged 18-70 years)
- Stable extent of hair loss over the last 6-months
- Severe to very-severe AA:
 - SALT ≥ 50
 - No other causes of alopecia
- Systemic Biologic and JAK-inhibitor naïve

Primary Endpoints

- The primary endpoint for this study is the least-square mean percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36.

Secondary Endpoints

- Percent change from baseline in SALT score at other timepoints
- Proportion of patients achieving improvement in Severity of Alopecia Tool (SALT) ≥ 50%, ≥ 75%, ≥ 90%
- Proportion of patients achieving an absolute SALT score ≤ 10, ≤ 20, ≤ 30
- Safety and tolerability

STUDY STATUS

Location of Planned Study Sites

- International multicenter study
- Approximately 26 clinical sites across Canada, Poland and United States



- This study is initiating in North America and other parts of the world (Figure 3):
 - North America (Canada, United States)
 - Europe (Poland)
- Additional details are available at clinicaltrials.gov: NCT06340360
- Please contact the Sponsor (Nektar) with any questions

